How Clinical Supply Teams Can Prevent Cross-Border Shipping Delays

By Joseph Weiford, global trade compliance professional

Clinical trials today are truly global enterprises, and the ability to move investigational medicinal products (IMPs) safely, securely, and compliantly has become one of the most important operational challenges facing clinical supply leaders. While scientific innovation drives the development of therapies, operational execution determines whether those therapies reach patients participating in clinical trials.

Drawing on years of observing international trade and regulatory systems in the context of border enforcement and compliance, I’ve developed a personal perspective on these challenges. Global trade systems are designed to balance the free flow of legitimate commerce with safeguards intended to protect public health, national security, and consumers. Clinical trial materials occupy a particularly sensitive position within this system because they often involve unapproved therapies, temperature-sensitive biologics, or highly valuable intellectual property.

Risks In Moving Investigational Products Across Borders

One of the most significant risks in transporting investigational products internationally is the complex regulatory status of the products themselves. Unlike commercial pharmaceuticals that have already been approved for market distribution, investigational products are typically shipped under clinical trial authorizations and may not yet have full regulatory approval in the importing country. This creates an additional layer of scrutiny during import processing.

Authorities such as the FDA and customs agencies responsible for border control frequently require documentation that clearly links a shipment to an authorized clinical study. If documentation is incomplete, inconsistent, or incorrectly classified, shipments may be delayed while authorities verify the regulatory status of the product.

Another risk involves time sensitivity. Many investigational therapies — particularly biologics, gene therapies, or advanced cell therapies — have strict temperature and stability requirements. Delays of even a few hours can significantly reduce a product’s usable life. When clinical trial shipments encounter delays at a port of entry, the consequences can extend beyond logistics costs; patient dosing schedules may be disrupted and, in some cases, entire shipments may become unusable.

There is also an increasing focus on supply chain security. High-value investigational products can be targets for diversion, theft, or counterfeiting. Maintaining strict chain-of-custody controls and clear documentation throughout the transportation process is essential to preserving both product integrity and regulatory confidence.

Regulatory Requirements And Enforcement Priorities

Regulatory frameworks governing the import and export of investigational products are designed to ensure that only authorized therapies enter a country and that they are handled according to approved clinical protocols. These frameworks vary across jurisdictions, but they generally involve coordination between drug regulators and customs authorities.

For example, in the United States, clinical trial imports often require documentation demonstrating that the product is associated with an IND application overseen by the FDA. Similar oversight structures exist within the European Union through the European Medicines Agency.

Enforcement priorities at the border typically focus on verifying that shipments meet regulatory requirements and that they do not pose risks to public health or safety. This includes ensuring that:

• The product is properly declared and classified.
• Documentation accurately reflects the nature of the shipment.
• Import permits or clinical trial authorizations are valid.
• Handling and labeling requirements are met.

When documentation aligns clearly with regulatory requirements, shipments generally move efficiently through the clearance process. However, when information is incomplete or inconsistent, authorities may pause clearance while verifying the shipment’s legitimacy. In the context of time-sensitive clinical supplies, even routine verification steps can create operational challenges.

Practical Steps To Avoid Delays And Compliance Issues

Clinical supply teams can take several proactive steps to minimize the risk of delays when shipping investigational products internationally.

1. Coordinate Early With Regulatory And Trade Specialists

One of the most effective strategies is early coordination between clinical operations, regulatory affairs, and trade compliance teams. By reviewing documentation and entry procedures before shipments leave the manufacturing facility, organizations can ensure that required permits, product codes, and study authorizations are clearly documented.

2. Ensure Consistency Across All Documentation

Customs authorities rely heavily on documentation to determine whether shipments comply with regulatory requirements. Inconsistent information between commercial invoices, shipping documents, and regulatory filings can trigger additional review. Clinical supply teams should establish standardized documentation templates and validation procedures to reduce these risks.

3. Use Logistics Providers Experienced In Clinical Materials

Not all logistics providers are familiar with the unique regulatory and handling requirements associated with investigational products. Selecting transportation partners with experience in clinical trial logistics can significantly improve the reliability of international shipments.

4. Plan For Contingencies

Even well-prepared shipments can encounter unexpected disruptions due to weather, transportation issues, or administrative delays. Maintaining contingency plans — including backup supply inventory or alternative routing options — can help ensure continuity of patient dosing schedules.

Common Blind Spots In Clinical Supply Chain Compliance

One of the most common blind spots in clinical supply chain compliance is the assumption that logistics challenges are purely operational rather than regulatory. In reality, many delays occur because documentation does not clearly establish the regulatory status of the shipment.

Another frequent challenge is underestimating the complexity of international regulatory environments. Each country may have unique requirements related to import permits, labeling, language translation, or clinical trial authorization documentation. Failing to account for these requirements early in the planning process can create complications once shipments are already in transit.

A third blind spot involves supply chain visibility. Clinical supply teams may have excellent visibility into manufacturing and site inventory levels but limited insight into the status of shipments moving through international clearance processes. Improving transparency across the entire logistics chain is essential for identifying potential disruptions before they affect trial timelines.

The Role Of Emerging Technologies

Emerging technologies offer promising opportunities to improve both visibility and compliance in clinical supply chains.

Digital documentation platforms can help ensure that shipment data remains consistent across all documentation and regulatory filings. By automating document generation and validation, these systems reduce the risk of human error and improve compliance with regulatory requirements.

Advanced tracking systems can provide real-time visibility into the location and condition of investigational product shipments. Continuous temperature monitoring and GPS tracking allow clinical supply teams to respond quickly if shipments encounter delays or environmental deviations.

Artificial intelligence also has the potential to support compliance monitoring by identifying anomalies in shipping documentation, classification codes, or routing patterns that could trigger regulatory scrutiny. When integrated with supply chain management systems, these technologies can provide early warnings that allow organizations to correct potential compliance issues before shipments reach the border.

Final Thoughts

The globalization of clinical research has made the movement of investigational products across borders more common and more complex than ever before. Clinical supply leaders play a critical role in ensuring that these shipments move efficiently while meeting the regulatory requirements designed to protect patients and public health.

By combining careful planning, strong regulatory coordination, experienced logistics partners, and emerging technology solutions, clinical supply teams can significantly reduce the risk of delays and disruptions. Ultimately, the goal of these efforts is not simply operational efficiency — it is ensuring that patients participating in clinical trials receive the therapies they depend on, when they need them.

The views expressed are solely those of the author and do not represent the views of any government agency or organization.

About The Author:

Joseph Weiford is a global trade compliance professional with extensive experience in international supply chain risk, regulatory enforcement, and cross-border commerce. His work focuses on helping organizations navigate complex regulatory environments and maintain compliance while moving sensitive or high-value goods internationally. Drawing on experience with U.S. Customs and Border Protection and deep knowledge of global trade systems, he provides insight into the intersection of logistics, regulation, and operational risk. Joseph writes on trade compliance, supply chain transparency, and emerging technologies shaping global commerce, with a focus on protecting consumers and strengthening compliant international trade.